Skip to main content
Erschienen in: Cancer Causes & Control 4/2008

01.05.2008 | Original Paper

Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?

verfasst von: Maria Dalamaga, Antigoni Lekka, Konstantinos Karmaniolas, Eleni Stathopoulou, Amalia Dionyssiou-Asteriou

Erschienen in: Cancer Causes & Control | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

Thyroid disease has been associated with leukemia and lymphoma. No previous study using clinical and laboratory data has explored whether thyroid disease and especially autoimmune thyroid disease (ATD) is associated with myelodysplastic syndrome (MDS) risk. In this case–control study, we investigated the association of ATD with MDS.

Methods

Our study included 101 cases with incident primary MDS confirmed by histology and cytogenetics, and 101 controls matched on gender and age, admitted for non-neoplastic and non-infectious diseases. All subjects were submitted to clinical, ultrasound thyroid evaluation and serum free T3, free T4, TSH, thyroglobulin, and thyroperoxidase antibodies determination.

Results

Adjusting for age, gender, and body mass index, there was statistically significant evidence that ATD is associated with increased risk of MDS (OR = 2.58, 95% CI 1.29–5.16). Interestingly, ATD starting from the remote past (more than 10 years from MDS onset) was positively associated with MDS risk (OR = 5.73. 95% CI 2.03–16.16). Mean serum levels of fT3, fT4, and thyroid antibodies were significantly higher in MDS patients and mean TSH serum levels were significantly lower in MDS patients than in controls (p < 0.05).

Conclusion

Biological plausibility and empirical evidence highlights the importance of ATD in MDS etiopathogenesis. Further studies are needed to explore underlying mechanisms associating thyroid autoimmunity with leukemogenesis.
Literatur
1.
Zurück zum Zitat Block M, Jacobsen LO, Bethard WF (1953) Preleukemic acute human leukemia. JAMA 152:1018–1028 Block M, Jacobsen LO, Bethard WF (1953) Preleukemic acute human leukemia. JAMA 152:1018–1028
2.
Zurück zum Zitat List AF, Doll DF (1999) The myelodysplastic syndromes. In: GR Foerster LJ, Lukens, Paraskevas F, Greer JP, Rodgers GM (eds) Wintrobe’s clinical hematology, vol 2, 10th ed. Williams and Wilkins, Baltimore, pp 2320–2333 List AF, Doll DF (1999) The myelodysplastic syndromes. In: GR Foerster LJ, Lukens, Paraskevas F, Greer JP, Rodgers GM (eds) Wintrobe’s clinical hematology, vol 2, 10th ed. Williams and Wilkins, Baltimore, pp 2320–2333
3.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of MDS. Br J Haematol 51:189–199PubMed Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of MDS. Br J Haematol 51:189–199PubMed
4.
Zurück zum Zitat Aul C, Germing U, Gattermann N, Minning H (1998) Increasing incidence of myelodysplastic syndromes: real or fictitious?. Leuk Res 22:93–100PubMedCrossRef Aul C, Germing U, Gattermann N, Minning H (1998) Increasing incidence of myelodysplastic syndromes: real or fictitious?. Leuk Res 22:93–100PubMedCrossRef
5.
Zurück zum Zitat Bennett JM, Komrokji RS (2005) The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 10:258–269PubMedCrossRef Bennett JM, Komrokji RS (2005) The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 10:258–269PubMedCrossRef
6.
Zurück zum Zitat Pasqualetti P, Festuccia V, Acitelli P, Collacciani A, Giusti A, Casale R (1997) Tobacco smoking and risk of hematological malignancies in adults: a case–control study. Br J Haematol 97:659–662PubMedCrossRef Pasqualetti P, Festuccia V, Acitelli P, Collacciani A, Giusti A, Casale R (1997) Tobacco smoking and risk of hematological malignancies in adults: a case–control study. Br J Haematol 97:659–662PubMedCrossRef
7.
Zurück zum Zitat Bjork J, Albin M, Mauritzon N, Stromberg U, Johansson B, Hagmar L (2000) Smoking and myelodysplastic syndromes. Epidemiology 11:285–291PubMedCrossRef Bjork J, Albin M, Mauritzon N, Stromberg U, Johansson B, Hagmar L (2000) Smoking and myelodysplastic syndromes. Epidemiology 11:285–291PubMedCrossRef
8.
Zurück zum Zitat Dalamaga M, Petridou E, Cook FE, Trichopoulos D (2002) Risk factors for myelodysplastic syndromes: a case–control study in Greece. Cancer Causes Control 3:603–608CrossRef Dalamaga M, Petridou E, Cook FE, Trichopoulos D (2002) Risk factors for myelodysplastic syndromes: a case–control study in Greece. Cancer Causes Control 3:603–608CrossRef
9.
Zurück zum Zitat Ido M., Nagata C, Kawakami N et al (1996) A case–control study of myelodysplastic syndromes among Japanese men and women. Leuk Res 20:727–731PubMedCrossRef Ido M., Nagata C, Kawakami N et al (1996) A case–control study of myelodysplastic syndromes among Japanese men and women. Leuk Res 20:727–731PubMedCrossRef
10.
Zurück zum Zitat Ross JA, Parker E, Blair CK, Cerhan JR, Folsom AR (2004) Body mass index and risk of leukemia in older women. Cancer Epidemiol Biomarkers Prev 13:1810–1813PubMedCrossRef Ross JA, Parker E, Blair CK, Cerhan JR, Folsom AR (2004) Body mass index and risk of leukemia in older women. Cancer Epidemiol Biomarkers Prev 13:1810–1813PubMedCrossRef
11.
Zurück zum Zitat Wolk A, Gridley G Svensson M et al (2001) A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12:13–21PubMedCrossRef Wolk A, Gridley G Svensson M et al (2001) A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12:13–21PubMedCrossRef
12.
Zurück zum Zitat Calle EE, Rodriguez C, Walker-Thurmond K, Thun M (2003) Overweight, obesity, and mortality from cancer in a prospective studied cohort of US adults. N Engl J Med 348:1625–1638PubMedCrossRef Calle EE, Rodriguez C, Walker-Thurmond K, Thun M (2003) Overweight, obesity, and mortality from cancer in a prospective studied cohort of US adults. N Engl J Med 348:1625–1638PubMedCrossRef
13.
Zurück zum Zitat Hamblin TJ (1996) Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 33:150–162PubMed Hamblin TJ (1996) Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 33:150–162PubMed
14.
Zurück zum Zitat Billstrom R, Johansson H, Johansson B, Mitelman F (1995) Immune-mediated complications in patients with myelodysplastic syndromes-clinical and cytogenetic features. Eur J Haematol 55:42–48PubMedCrossRef Billstrom R, Johansson H, Johansson B, Mitelman F (1995) Immune-mediated complications in patients with myelodysplastic syndromes-clinical and cytogenetic features. Eur J Haematol 55:42–48PubMedCrossRef
15.
Zurück zum Zitat Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG (2004) Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 34:690–700PubMedCrossRef Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG (2004) Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 34:690–700PubMedCrossRef
16.
Zurück zum Zitat Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W (1995) Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 91: 403–408PubMedCrossRef Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W (1995) Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 91: 403–408PubMedCrossRef
17.
Zurück zum Zitat Saenger EL, Thomas GE, Tompkins EA (1968) Incidence of leukemia following treatment of hyperthyroidism. JAMA 205:855–862PubMedCrossRef Saenger EL, Thomas GE, Tompkins EA (1968) Incidence of leukemia following treatment of hyperthyroidism. JAMA 205:855–862PubMedCrossRef
18.
Zurück zum Zitat Moskowitz C, Dutcher JP, Wiernik PH (1992) Association of thyroid disease with acute leukemia. Am J Hematol 39:102–107PubMedCrossRef Moskowitz C, Dutcher JP, Wiernik PH (1992) Association of thyroid disease with acute leukemia. Am J Hematol 39:102–107PubMedCrossRef
19.
Zurück zum Zitat Goldman MB, Monson RR, Maloof F (1990) Cancer mortality in women with thyroid disease. Cancer Res 50:2283–2289PubMed Goldman MB, Monson RR, Maloof F (1990) Cancer mortality in women with thyroid disease. Cancer Res 50:2283–2289PubMed
20.
Zurück zum Zitat Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed
21.
Zurück zum Zitat Aghini-Lombardi F, Pinchera A, Antonangeli L, Ragho T, Fenzi GF, Nanni P, Vitti P (1993) Iodized salt prophylaxis of endemic goiter: an experience in Toscana (Italy). Acta Endocrinologica 129: 497–500PubMed Aghini-Lombardi F, Pinchera A, Antonangeli L, Ragho T, Fenzi GF, Nanni P, Vitti P (1993) Iodized salt prophylaxis of endemic goiter: an experience in Toscana (Italy). Acta Endocrinologica 129: 497–500PubMed
22.
Zurück zum Zitat Marcocci C, Vitti P, Cetani F, Catalano F, Concetti R, Pinchera A (1991) Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. J Clin Endocrinol Metab 72:209–213PubMedCrossRef Marcocci C, Vitti P, Cetani F, Catalano F, Concetti R, Pinchera A (1991) Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. J Clin Endocrinol Metab 72:209–213PubMedCrossRef
23.
Zurück zum Zitat Markou A (2006) Determination of thyroid hormones reference ranges in Greek population. Master’s thesis. Laboratory of Clinical Biochemistry, Attikon General University Hospital, Athens University School of Medicine Markou A (2006) Determination of thyroid hormones reference ranges in Greek population. Master’s thesis. Laboratory of Clinical Biochemistry, Attikon General University Hospital, Athens University School of Medicine
24.
Zurück zum Zitat Breslow NE, Day NE (1980) The analysis of case–control studies. In: Statistical methods in cancer research, vol I. International Agency for Research on Cancer, IARC Scientific Publications; No 32, Lyon, France Breslow NE, Day NE (1980) The analysis of case–control studies. In: Statistical methods in cancer research, vol I. International Agency for Research on Cancer, IARC Scientific Publications; No 32, Lyon, France
25.
Zurück zum Zitat SAS Institute Inc. (1989) SAS/STAT User’s Guide 1989, 4th edn. Cary, NC SAS Institute Inc. (1989) SAS/STAT User’s Guide 1989, 4th edn. Cary, NC
26.
Zurück zum Zitat Holm LE, Blomgren H, Lowhagen T (1985) Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 312:601–604PubMedCrossRef Holm LE, Blomgren H, Lowhagen T (1985) Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 312:601–604PubMedCrossRef
27.
Zurück zum Zitat Munoz JM, Gorman CA, Elveback LR, Wentz JR (1978) Incidence of malignant neoplasms of all types in patients with Graves’ disease. Arch Intern Med 138:944–947PubMedCrossRef Munoz JM, Gorman CA, Elveback LR, Wentz JR (1978) Incidence of malignant neoplasms of all types in patients with Graves’ disease. Arch Intern Med 138:944–947PubMedCrossRef
28.
Zurück zum Zitat Haubenstock A, Zalusky R (1985) Autoimmune-hyperthyroidism and thrombocytopenia developing in a patient with chronic lymphocytic leukemia. Am J Hematol 19:281–283PubMedCrossRef Haubenstock A, Zalusky R (1985) Autoimmune-hyperthyroidism and thrombocytopenia developing in a patient with chronic lymphocytic leukemia. Am J Hematol 19:281–283PubMedCrossRef
29.
Zurück zum Zitat Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H (2002) In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 26:677–686PubMedCrossRef Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H (2002) In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 26:677–686PubMedCrossRef
30.
Zurück zum Zitat Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R (2005) Over-expression of tumor necrosis factor-alpha from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 75:485–491PubMedCrossRef Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R (2005) Over-expression of tumor necrosis factor-alpha from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 75:485–491PubMedCrossRef
31.
Zurück zum Zitat Hamburger JI (1986) The various presentations of thyroiditis. Ann Int Med 104: 219–224PubMed Hamburger JI (1986) The various presentations of thyroiditis. Ann Int Med 104: 219–224PubMed
32.
Zurück zum Zitat Nielsen CH, Hegedus L, Rieneck K, Moeller AC, Leslie RG, Bendtzen K (2007) Production of interleukin-5 and IL-15 accompanies T helper cell type 1 (Th1) cytokine responses to a major self-antigen, thyroglobulin, in health and autoimmune thyroid disease. Clin Exp Immunol 147:287–295PubMedCrossRef Nielsen CH, Hegedus L, Rieneck K, Moeller AC, Leslie RG, Bendtzen K (2007) Production of interleukin-5 and IL-15 accompanies T helper cell type 1 (Th1) cytokine responses to a major self-antigen, thyroglobulin, in health and autoimmune thyroid disease. Clin Exp Immunol 147:287–295PubMedCrossRef
33.
Zurück zum Zitat Drugarin D, Negru S, Koreck A, Zosin I, Cristea C (2000) The pattern of a TH1 cytokine in autoimmune thyroiditis. Immunol Lett 71: 73–77PubMedCrossRef Drugarin D, Negru S, Koreck A, Zosin I, Cristea C (2000) The pattern of a TH1 cytokine in autoimmune thyroiditis. Immunol Lett 71: 73–77PubMedCrossRef
34.
Zurück zum Zitat Perillat-Menegaux F, Clavel J, Auclerc MF et al (2003) Family history of autoimmune thyroid disease and childhood leukemia. Cancer Epidemiol Biomarkers Prev 12:60–63PubMed Perillat-Menegaux F, Clavel J, Auclerc MF et al (2003) Family history of autoimmune thyroid disease and childhood leukemia. Cancer Epidemiol Biomarkers Prev 12:60–63PubMed
35.
Zurück zum Zitat Lei U, Wohlfahrt J, Hjalgrim H, Hjalgrim LL, Simonsen H, Melbye M (2000) Neonatal level of thyroid-stimulating hormone and acute childhood leukemia. Int J Cancer 88:486–488PubMedCrossRef Lei U, Wohlfahrt J, Hjalgrim H, Hjalgrim LL, Simonsen H, Melbye M (2000) Neonatal level of thyroid-stimulating hormone and acute childhood leukemia. Int J Cancer 88:486–488PubMedCrossRef
36.
Zurück zum Zitat Umesono K, Giguere V, Glass CK, Rosenfeld MG, Evans RM (1988) Retinoic acid and thyroid hormone induce gene expression through a common response element. Nature 336:262–265PubMedCrossRef Umesono K, Giguere V, Glass CK, Rosenfeld MG, Evans RM (1988) Retinoic acid and thyroid hormone induce gene expression through a common response element. Nature 336:262–265PubMedCrossRef
37.
Zurück zum Zitat Hudson LG, Santon JB, Glass CK, Gill GN (1990) Ligand-activated thyroid hormone and retinoic acid receptors inhibit growth factor receptor promoter expression. Cell 62:1165–1175PubMedCrossRef Hudson LG, Santon JB, Glass CK, Gill GN (1990) Ligand-activated thyroid hormone and retinoic acid receptors inhibit growth factor receptor promoter expression. Cell 62:1165–1175PubMedCrossRef
38.
Zurück zum Zitat Bernal J, Andersson LC (1984) The nuclear 3,5,3’-triiodothyronine receptor in human leukaemic cell lines. Acta Endocrinol (Copenh) 105:429–432 Bernal J, Andersson LC (1984) The nuclear 3,5,3’-triiodothyronine receptor in human leukaemic cell lines. Acta Endocrinol (Copenh) 105:429–432
39.
Zurück zum Zitat Giustarini E, Pinchera A, Fierabracci P, Ronchella M, Fustaino L, Mammoli C, Giani C (2006) Thyroid autoimmunity in patients with malignant and benign breast disease before surgery. Eur J Endocrinol 154:645–649PubMedCrossRef Giustarini E, Pinchera A, Fierabracci P, Ronchella M, Fustaino L, Mammoli C, Giani C (2006) Thyroid autoimmunity in patients with malignant and benign breast disease before surgery. Eur J Endocrinol 154:645–649PubMedCrossRef
Metadaten
Titel
Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?
verfasst von
Maria Dalamaga
Antigoni Lekka
Konstantinos Karmaniolas
Eleni Stathopoulou
Amalia Dionyssiou-Asteriou
Publikationsdatum
01.05.2008
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 4/2008
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9096-3

Weitere Artikel der Ausgabe 4/2008

Cancer Causes & Control 4/2008 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.